2 top FTSE 100 shares to buy right now

Here are two FTSE 100 shares that operate in booming sectors that I think are excellent growth options for my long-term portfolio right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 index is trading steadily at its highest levels since the pandemic. It’s up 3.3% in the last month, dispelling my concerns of a potential market crash after the Evergrande collapse in China. I think it’s a great time to catch some excellent shares on their way up and here are the three UK shares I’m watching closely now.

Pharma drama

Over the last decade, the pharma sector has been under scrutiny for hiking the prices of life-saving drugs. Distrust of big pharma is at an all-time high in some quarters with the pandemic fuelling existing concerns over the cost of medication. I think FTSE 100 company Hikma Pharmaceuticals (LSE:HIK) addresses this issue.

The pharma company specialises in low-cost, generic versions of popular medication. This is an area that I think shows a lot of promise. Although R&D in the field of medicine is paramount, I think the ageing British (and global) population will benefit from low-cost treatment options as well.

From a potential investor’s perspective, a return of -4.3% in 2021 might seem like a red flag, but when I look at the five-year graph, Hikma shares have increased steadily, offering a robust 51% return. The first-half 2021 report makes for good reading. Revenue was up 7% to US$1.2bn and operating profits were up 10% at $326mn.

But, Hikma shares have had a turbulent run in the market over the last five years. This tells me that shareholder confidence isn’t great. And there are concerns surrounding inflated revenue in the injectables division of the company, which received a temporary sales boost during the pandemic. This is expected to drop in the coming months, which could dent revenue.

However, the company looks like a good long-term investment for my portfolio and operates in a sector that I think will remain crucial. It’s on my FTSE 100 shares to buy list for November.

Mining share up 125% in a year

Glencore (LSE:GLEN) is the world’s largest commodity trader with large mining operations as well. The company has 26 coal mines around the world and is a major producer of cobalt, copper and Nickel — all crucial components in electric vehicle (EV) manufacture.

Commodities prices are rising globally and I think Glencore stands to gain a lot from this. When I look at its market performance, the whopping 125% returns in 12-months are impressive. And they come with a 2.4% dividend yield as well. Its shares are currently on a small downtrend, falling 2.7% in the last week. I think its current price of 253p is an excellent entry point for my portfolio.

The company’s 2021 half-year report showed a 32% increase in revenue to US$93.8bn, a 4% increase in total assets to $122.4bn and a 33% decrease in net debt, which stood at $10.6bn.

The mining company is also well-positioned to cash in on the coal shortage in Asia. But over the long term, commodities prices could normalise, which will cut into Glencore’s profits. And there are ethical concerns and the environmental impact of the mining sector as a whole (especially coal), which Glencore will have to address in the coming years. But I think the surge in construction after the pandemic and the increase in production in EVs sets up Glencore for sustained returns, which is why it also makes my FTSE 100 buy list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Suraj Radhakrishnan has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »